Myokardia Europe BV


Science Park 408
1098 XH

cardiac medicines

Mavacamten for patients with Hypertrophic Cardiomyopathy (HCM) and other medicines for heart diseases


Myokardia pioneers a precision medicine approach to treating cardiomyopathies and other forms of heart failure that results from biomechanical defects in cardiac muscle contraction. Myokardia Netherlands serves as the European Headquarters and is focused on bringing the first product mavacamten to HCM patients in Europe

Founded: Myokardia Inc was founded in 2012 in California
Situated in Amsterdam Science Park: Sept 1st 2020
Number of employees: About 8 by end of 2020 growing to 20-25 by end of 2022